...
search icon
gdtc-img

CytoMed Therapeutics Limited Ordinary Shares, Common Stock

GDTC

NAQ

$2.5

-$0.21

(-7.75%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$29.95M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
11.79K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.2 L
$4.05 H
$2.5

About CytoMed Therapeutics Limited Ordinary Shares, Common Stock

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGDTCSectorS&P500
1-Week Return-11.03%-0.2%-1.38%
1-Month Return-7.06%2.04%-4.79%
3-Month Return-9.09%3.59%-4.48%
6-Month Return54.32%-4.15%5%
1-Year Return20.77%2%12.66%
3-Year Return-37.5%14.91%35.37%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-44.92K84.18K270.34K290.56K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":15.46,"profit":true},{"date":"2021-12-31","value":28.97,"profit":true},{"date":"2022-12-31","value":93.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue-3.50K2.59K6.48K77.47K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":4.51,"profit":true},{"date":"2021-12-31","value":3.34,"profit":true},{"date":"2022-12-31","value":8.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit-41.43K81.59K263.86K213.09K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":15.7,"profit":true},{"date":"2021-12-31","value":30.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.76,"profit":true}]
Gross Margin-92.22%96.92%97.60%73.34%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":94.48,"profit":true},{"date":"2021-12-31","value":99.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":75.14,"profit":true}]
Operating Expenses823.53K949.00K1.28M1.38M3.12M[{"date":"2019-12-31","value":26.38,"profit":true},{"date":"2020-12-31","value":30.4,"profit":true},{"date":"2021-12-31","value":40.94,"profit":true},{"date":"2022-12-31","value":44.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(815.88K)(949.00K)(1.43M)(1.40M)(2.91M)[{"date":"2019-12-31","value":-81588300,"profit":false},{"date":"2020-12-31","value":-94900341,"profit":false},{"date":"2021-12-31","value":-143258127,"profit":false},{"date":"2022-12-31","value":-140252813,"profit":false},{"date":"2023-12-31","value":-291199700,"profit":false}]
Total Non-Operating Income/Expense-(618.74K)(435.29K)(1.05M)14.93K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-4143.41,"profit":false},{"date":"2021-12-31","value":-2914.92,"profit":false},{"date":"2022-12-31","value":-7001.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(850.76K)(1.47M)(1.53M)(2.33M)(3.13M)[{"date":"2019-12-31","value":-85076100,"profit":false},{"date":"2020-12-31","value":-146721816,"profit":false},{"date":"2021-12-31","value":-153398705,"profit":false},{"date":"2022-12-31","value":-232500767,"profit":false},{"date":"2023-12-31","value":-313150100,"profit":false}]
Income Taxes-84.71K(53.43K)1.22K373.69[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-63.07,"profit":false},{"date":"2022-12-31","value":1.44,"profit":true},{"date":"2023-12-31","value":0.44,"profit":true}]
Income After Taxes-(1.55M)(1.48M)(2.33M)(3.13M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-155192774,"profit":false},{"date":"2021-12-31","value":-148055970,"profit":false},{"date":"2022-12-31","value":-232622596,"profit":false},{"date":"2023-12-31","value":-313187469,"profit":false}]
Income From Continuous Operations-(1.94M)(2.05M)(3.13M)(4.13M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-193562600,"profit":false},{"date":"2021-12-31","value":-205190300,"profit":false},{"date":"2022-12-31","value":-313145200,"profit":false},{"date":"2023-12-31","value":-413317000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(850.76K)(1.47M)(1.53M)(2.40M)(3.13M)[{"date":"2019-12-31","value":-85076100,"profit":false},{"date":"2020-12-31","value":-146721816,"profit":false},{"date":"2021-12-31","value":-153398705,"profit":false},{"date":"2022-12-31","value":-239791478,"profit":false},{"date":"2023-12-31","value":-313178800,"profit":false}]
EPS (Diluted)----(0.20)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-20,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GDTC
Cash Ratio 18.08
Current Ratio 21.53

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GDTC
ROA (LTM) -17.44%
ROE (LTM) -26.26%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GDTC
Debt Ratio Lower is generally better. Negative is bad. 0.07
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.93

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GDTC
Trailing PE NM
Forward PE NM
P/S (TTM) 69.85
P/B 4.10
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is CytoMed Therapeutics Limited Ordinary Shares share price today?

CytoMed Therapeutics Limited Ordinary Shares (GDTC) share price today is $2.5

Can Indians buy CytoMed Therapeutics Limited Ordinary Shares shares?

Yes, Indians can buy shares of CytoMed Therapeutics Limited Ordinary Shares (GDTC) on Vested. To buy CytoMed Therapeutics Limited Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GDTC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of CytoMed Therapeutics Limited Ordinary Shares be purchased?

Yes, you can purchase fractional shares of CytoMed Therapeutics Limited Ordinary Shares (GDTC) via the Vested app. You can start investing in CytoMed Therapeutics Limited Ordinary Shares (GDTC) with a minimum investment of $1.

How to invest in CytoMed Therapeutics Limited Ordinary Shares shares from India?

You can invest in shares of CytoMed Therapeutics Limited Ordinary Shares (GDTC) via Vested in three simple steps:

  • Click on Sign Up or Invest in GDTC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in CytoMed Therapeutics Limited Ordinary Shares shares
What is CytoMed Therapeutics Limited Ordinary Shares 52-week high and low stock price?

The 52-week high price of CytoMed Therapeutics Limited Ordinary Shares (GDTC) is $4.05. The 52-week low price of CytoMed Therapeutics Limited Ordinary Shares (GDTC) is $1.2.

What is CytoMed Therapeutics Limited Ordinary Shares price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of CytoMed Therapeutics Limited Ordinary Shares (GDTC) is 4.10

What is the Market Cap of CytoMed Therapeutics Limited Ordinary Shares?

The market capitalization of CytoMed Therapeutics Limited Ordinary Shares (GDTC) is $29.95M

What is CytoMed Therapeutics Limited Ordinary Shares’s stock symbol?

The stock symbol (or ticker) of CytoMed Therapeutics Limited Ordinary Shares is GDTC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top